How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth? Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Healthcare stocks with a solid history of dividend growth are attractive to investors seeking reliable income. Here, we highlight three companies—Amgen, Merck, and AbbVie—that have demonstrated consistent dividend increases. Amgen Amgen (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics globally. The company serves various healthcare providers, including physicians, clinics, dialysis centers, hospitals, and pharmacies. Amgen has maintained dividend payments for 14 consecutive years and raised them for 13 years. The company pays a quarterly dividend of $2.25 per share, or $9 annually, yielding 2.83%. Over the past twelve months, Amgen generated $29.5 billion in revenue and $3.76 billion in net income. Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York. Investing in its booming real estate market has never been more accessible. Merck Merck & Co., Inc. (NYSE:MRK) operates as a global healthcare company through its Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers products for oncology, acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. The Animal Health segment provides veterinary pharmaceuticals, vaccines, and health management solutions. Merck has raised its dividend for 13 consecutive years and pays a quarterly dividend of $0.77 per share, or $3.08 annually, yielding 2.32%. The stock is up more than 23% YTD, and the company has beaten EPS and revenue estimates for the last 11 quarters. Over the past twelve months, Merck generated $61.4 billion in revenue and $2.3 billion in net income. AbbVie AbbVie (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide, focusing on key therapeutic areas such as immunology, oncology, neuroscience, and eye care. AbbVie has raised its dividend for 11 consecutive years and pays a quarterly dividend of $1.55 per share, or $6.20 annually, yielding 3.59%. Over the past twelve months, AbbVie generated $54.4 billion in revenue and $5.99 billion in net income. Don’t Miss: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, and you only need $100. Are You Missing Out On Higher Yields? The current high-interest-rate environment has created an incredible opportunity for income-seeking investors to earn massive yields, but not through dividend stocks... Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities and Benzinga has identified some of the most attractive options for you to consider. For example, the Jeff Bezos-backed investment platform just launched its Private Credit Fund, which provides access to a pool of short-term loans backed by residential real estate with a target 7% to 9% net annual yield paid to investors monthly. The best part? Unlike other private credit funds, this one has a minimum investment of only $100. Don't miss out on this opportunity to take advantage of high-yield investments while rates are high. Check out Benzinga's favorite high-yield offerings. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. This article How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth? originally appeared on Benzinga.com
How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...